E-submission
Search
- Page Path
- HOME > Search
Original Article
- Clinical and Prognostic Significances of Cytokeratin 19 and KIT Expression in Surgically Resectable Pancreatic Neuroendocrine Tumors
- Eun-Mi Son, Joo Young Kim, Soyeon An, Ki-Byung Song, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
- J Pathol Transl Med. 2015;49(1):30-36. Published online January 15, 2015
- DOI: https://doi.org/10.4132/jptm.2014.10.23
- 10,740 View
- 101 Download
- 19 Web of Science
- 18 Crossref
-
Abstract
PDF - Background
Pancreatic neuroendocrine tumors (PanNETs) are malignant endocrine neoplasms that present diverse clinical behaviors. Therefore, identification of biomarkers of PanNETs is important for stratification of the prognosis of PanNET patients. Recently, cytokeratin 19 (CK19) and KIT expression were reported to have prognostic significance in PanNET patients. Methods: To identify their prognostic significance, CK19 and KIT protein expression were assessed in 182 surgically resected PanNETs and compared with clinicopathologic factors. Results: Of 182 PanNETs cases, CK19 and KIT expression was noted in 97 (53.3%) and 16 (8.8%) cases, respectively. PanNET patients with CK19 expression had larger tumors (p=.006), higher World Health Organization (WHO) grade (p=.002) and pT classification (p<.001), increased distant metastasis (p=.004), and lymphovascular (p=.012) and perineural (p=.019) invasion. Similarly, those with KIT expression had larger tumors (p=.030), higher WHO grade (p=.001), advanced pT classification (p<.001), distant metastasis (p=.001), and lymphovascular invasion (p=.014). The 5-year survival rate for PanNET patients with KIT expression was significantly lower (62%) than that of patients without KIT expression (77%, p=.011), as determined by univariate but not by multivariate analyses. Conclusions: CK19 and KIT expression correlate with higher metastatic potential and advanced disease stage, and KIT expression is associated with worse survival in PanNET patients. -
Citations
Citations to this article as recorded by
- Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy
Kahoko Maeda, Takeshi Uehara, Waki Hosoda, Yasuhiro Kuraishi, Hiroyoshi Ota
Pathology - Research and Practice.2024; 262: 155537. CrossRef - Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor
Bokyung Ahn, Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2023; 147(1): 100. CrossRef -
Tumor-associated nonmyelinating Schwann cell–expressed
PVT1
promotes pancreatic cancer kynurenine pathway and tumor immune exclusion
Chengcao Sun, Youqiong Ye, Zhi Tan, Yuan Liu, Yajuan Li, Wei Hu, Ke Liang, Sergey D. Egranov, Lisa Angela Huang, Zhao Zhang, Yaohua Zhang, Jun Yao, Tina K. Nguyen, Zilong Zhao, Andrew Wu, Jeffrey R. Marks, Abigail S. Caudle, Aysegul A. Sahin, Jianjun Gao,
Science Advances.2023;[Epub] CrossRef - Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
Anne Menz, Rifka Bauer, Martina Kluth, Clara Marie von Bargen, Natalia Gorbokon, Florian Viehweger, Maximilian Lennartz, Cosima Völkl, Christoph Fraune, Ria Uhlig, Claudia Hube-Magg, Noémi De Wispelaere, Sarah Minner, Guido Sauter, Simon Kind, Ronald Simo
Human Pathology.2021; 115: 19. CrossRef - The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities
Kate Young, Naureen Starling, Anguraj Sadanandam
Seminars in Cancer Biology.2020; 61: 132. CrossRef - Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours
Joo Young Kim, Jacqueline A. Brosnan-Cashman, Jiyoon Kim, Soyeon An, Kyoung-Bun Lee, Haeryoung Kim, Do Youn Park, Kee-Taek Jang, Young-Ha Oh, Ralph H. Hruban, Christopher M. Heaphy, Seung-Mo Hong
Pathology.2020; 52(3): 336. CrossRef - Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification
Yue Xue, Michelle D. Reid, Burcin Pehlivanoglu, Rebecca C. Obeng, Hongmei Jiang, Bahar Memis, Shu K. Lui, Juan Sarmiento, David Kooby, Shishir K. Maithel, Bassel El-Rayes, Olca Basturk, Volkan Adsay
Endocrine Pathology.2020; 31(3): 239. CrossRef - Histological grades and prognostic markers of well-differentiated pancreatic neuroendocrine tumor (WDPNET)
Yongchao Li, Daniel Rowan, Claire P. Williamson, Meiyun Fan, Ali G. Saad, Lizhi Zhang
Journal of Pancreatology.2020; 3(4): 188. CrossRef - Clinical and histopathologic prognostic implications of the expression of cytokeratins 8, 10, 13, 14, 16, 18 and 19 in oral and oropharyngeal squamous cell carcinoma
Rima A. Safadi, Niveen I. Abdullah, Rolla F. Alaaraj, Dima H. Bader, Darshan D. Divakar, Abed A. Hamasha, Maher A. Sughayer
Archives of Oral Biology.2019; 99: 1. CrossRef - Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
Lingaku Lee, Tetsuhide Ito, Robert T Jensen
Expert Review of Anticancer Therapy.2019; 19(12): 1029. CrossRef - Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
Virchows Archiv.2018; 472(5): 739. CrossRef - CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses
Yasuhiro Sakai, Seung-Mo Hong, Soyeon An, Joo Young Kim, Denis Corbeil, Jana Karbanová, Kyoko Otani, Kohei Fujikura, Ki-Byung Song, Song Cheol Kim, Masayuki Akita, Yoshihide Nanno, Hirochika Toyama, Takumi Fukumoto, Yonson Ku, Takanori Hirose, Tomoo Itoh,
Human Pathology.2017; 61: 148. CrossRef - Prognostic and predictive biomarkers in neuroendocrine tumours
David L. Chan, Stephen J. Clarke, Connie I. Diakos, Paul J. Roach, Dale L. Bailey, Simron Singh, Nick Pavlakis
Critical Reviews in Oncology/Hematology.2017; 113: 268. CrossRef - Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
Journal of Pathology and Translational Medicine.2017; 51(4): 388. CrossRef - Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis
Dong Cen, Jiang Chen, Zheyong Li, Jie Zhao, Xiujun Cai, Aamir Ahmad
PLOS ONE.2017; 12(11): e0187588. CrossRef - A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases
Liangtao Ye, Huilin Ye, Quanbo Zhou, Zhihua Li, Qing Lin, Langping Tan, Wenchao Gao, Zhiqiang Fu, Shangyou Zheng, Rufu Chen
International Journal of Surgery.2016; 29: 108. CrossRef - Correlating and Combining Genomic and Proteomic Assessment withIn VivoMolecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
Bhakti Basu, Sandip Basu
Cancer Biotherapy and Radiopharmaceuticals.2016; 31(3): 75. CrossRef - Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
- Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy
First
Prev
